Vascular differences between IDH‐wildtype glioblastoma and astrocytoma IDH‐mutant grade 4 at imaging and transcriptomic levels

Abstract

Global agreement in central nervous system (CNS) tumor classification is essential for predicting patient prognosis and determining the correct course of treatment, as well as for stratifying patients for clinical trials at international level. The last update by the World Health Organization of CNS tumor classification and grading in 2021 considered, for the first time, IDH‐wildtype glioblastoma and astrocytoma IDH‐mutant grade 4 as different tumors. Mutations in the genes isocitrate dehydrogenase (IDH) 1 and 2 occur early and, importantly, contribute to gliomagenesis. IDH mutation produces a metabolic reprogramming of tumor cells, thus affecting the processes of hypoxia and vascularity, resulting in a clear advantage for those patients who present with IDH‐mutated astrocytomas. Despite the clinical relevance of IDH mutation, current protocols do not include full sequencing for every patient. Alternative biomarkers could be useful and complementary to obtain a more reliable classification. In this sense, magnetic resonance imaging (MRI)‐perfusion biomarkers, such as relative cerebral blood volume and flow, could be useful from the moment of presurgery, without incurring additional financial costs or requiring extra effort. The main purpose of this work is to analyze the vascular and hemodynamic differences between IDH‐wildtype glioblastoma and IDH‐mutant astrocytoma. To achieve this, we evaluate and validate the association between dynamic susceptibility contrast‐MRI perfusion biomarkers and IDH mutation status. In addition, to gain a deeper understanding of the vascular differences in astrocytomas depending on the IDH mutation, we analyze the transcriptomic bases of the vascular differences.

DSC-PWI presurgical differentiation of grade 4 astrocytoma and glioblastoma in young adults: rCBV percentile analysis across enhancing and non-enhancing regions

“…Our literature search yielded only two DSC-PWI studies explicitly focused on grade 4 astrocytic tumors [28,29], which in general terms reported higher rCBV values in IDHwildtype tumors. However, due to different methodological approaches, direct comparison of results is not feasible.…”